Chronic Lymphocytic Leukemia: Clinical Stages Maintain Their Prognostic Significance Over the Course of the Disease and Are Surrogates for Response to Therapy

Vicente, Eva Puy; Cuéllar-García, Carolina; Martinez, Montserrat; Soler, A.; Mora, Alba; Bosch, Rosa; Brunet, Salut; Briones, Javier; García, Irene Carrasco; Esquirol, Albert; Granell, Miquel; Saavedra, Silvana; Nomdedeu, Josep; Sierra, Jorge; Martino, Rodrigo; Moreno, Carol

doi:10.1016/j.clml.2018.06.023

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TTNT is a well-accepted endpoint in clinical trials of patients with multiple myeloma [ 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 ]. It also features in the published literature of clinical studies of patients with chronic lymphocytic leukaemia [ 29 , 30 , 31 , 32 , 33 , 34 ], follicular lymphoma [ 35 , 36 , 37 , 38 , 39 ], mantle cell lymphoma [ 40 ], amyloidosis [ 41 ], Waldenstrom macroglobulinaemia [ 42 , 43 ], autoimmune haemolytic anaemia [ 44 ], metastatic melanoma [ 45 ], and metastatic breast cancer [ 46 ]. TTNT has also been used as a valid endpoint within cost-benefit analyses in several published health-economic analyses [ 19 , 24 , 27 , 29 ].…”

Section: Use Of Ttnt In Other Diseasesmentioning

confidence: 99%

Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma

Campbell

Scarisbrick

Kim

et al. 2020

Cancers

View full text Add to dashboard Cite

Time to next treatment (TTNT) is an emerging endpoint in clinical studies of primary cutaneous T-cell lymphomas (CTCL), with utility as a surrogate marker for the “duration of clinical benefit”. TTNT provides a highly clinically meaningful endpoint that uniquely reflects not only the duration of treatment efficacy on disease and symptom control, but also incorporates the patient experience by accounting for patient compliance and tolerance to the studied therapy(s). Given the distinct challenges of pin-pointing the exact date of progression in patients with multi-compartmental CTCL, TTNT overcomes many of the shortcomings of conventional, disease-focused, clinical endpoints in primary CTCL research. Although widely accepted in clinical research for numerous other incurable malignancies, TTNT currently lacks a standardised definition. In this paper, we describe the value of TTNT as a clinical endpoint, review the applications of TTNT in primary CTCL research, and propose a standardised definition of TTNT to be applied in future clinical research of primary CTCL therapies.

show abstract